Intervention Review

You have free access to this content

Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer

  1. Tiago B de Castria1,*,
  2. Edina MK da Silva2,
  3. Aecio FT Gois3,
  4. Rachel Riera4

Editorial Group: Cochrane Lung Cancer Group

Published Online: 16 AUG 2013

Assessed as up-to-date: 13 MAR 2013

DOI: 10.1002/14651858.CD009256.pub2


How to Cite

de Castria TB, da Silva EMK, Gois AFT, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD009256. DOI: 10.1002/14651858.CD009256.pub2.

Author Information

  1. 1

    Instituto do Câncer do Estado de Sao Paulo (ICESP/FMUSP), Clinical Oncology, São Paulo, Brazil

  2. 2

    Universidade Federal de São Paulo, Emergency Medicine and Evidence Based Medicine, São Paulo, São Paulo, Brazil

  3. 3

    Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil

  4. 4

    Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde, Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil

*Tiago B de Castria, Clinical Oncology, Instituto do Câncer do Estado de Sao Paulo (ICESP/FMUSP), Av. Doutor Arnaldo 251 - Cerquiera César, São Paulo, 01246-000, Brazil. tiagobiachi@yahoo.com.br.

Publication History

  1. Publication Status: New
  2. Published Online: 16 AUG 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Cai 2002 {published data only}
  • Cai X, Chen P, Yin X, Li Q. Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2002;5(6):427-8.
Chen 2006 {published data only}
  • Chen YM, Perng RP, Tsai CM, Whang-Peng J. A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. Journal of Thoracic Oncology 2006;1(2):141-5.
Ferry 2011 {published and unpublished data}
  • Ferry D, Billingham L, Jarrett H, Dunlop D, Thompson J, Kumar M, et al. British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine (1250mg/m2) combined with cisplatin 50 mg/m2 (GC50) versus cisplatin 80 mg/m2 (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax 2011;66:A41.
Fossella 2003 {published data only}
  • Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology 2003;21(16):3016-24.
Mazzanti 2003 {published data only}
  • Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003;41(1):81-9.
Rosell 2002 {published data only}
  • Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology 2002;13(10):1539-49.
Schiller 2002 {published data only}
  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 2002;346(2):92-8.
Sweeney 2001 {published data only}
  • Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92(10):2639-47.
Yan 2001 {published data only}
  • Yan D, Wang G, Zhang G, Hu C. A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2001;4(3):188-90.
Zatloukal 2003 {published data only}
  • Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003;41(3):321-31.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Belani 2001 {published data only}
  • Belani C, TAX 326 Study Group. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis. Seminars in Oncology 2001;28(3):10-4.
Belani 2002 {published data only}
  • Belani CP, TAX 326 Study Group. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Seminars in Oncology 2002;29(3):4-9.
Belani 2006 {published data only}
  • Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 2006;53(2):231-9.
Fossella 2001 {published data only}
  • Fossella F. Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC): results of a multicenter, randomized phase III study. European Journal of Cancer 2001;37:S154.
Gatzemeier 1999 {published data only}
  • Gatzemeier U, Rosell R, Betticher D, Keppler U, Macha H, Pirker R, et al. Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer 1999;35(4):S246.
Macha 1998 {published data only}
  • Macha HN, Gatzemeier U, Betticher DC, Keppler U, Berthet P, Chemaissan A, et al. Randomized multicenter trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC): results of a planned interim analysis. Proceedings of the American Society of Clinical Oncology. Los Angeles, 1998; Vol. 17:465a (abstract 1789).
Mazzanti 2000 {published data only}
  • Mazzanti P, Lippe P, Battelli N, Mattioli R, Buzzi F, Trivisonne R, et al. Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (ANSCLC): a multicenter phase II randomized trial of a 21-day schedule. Preliminary results. Proceedings of the American Society of Clinical Oncology. New Orleans: American Society of Clinical Oncology, 2000; Vol. 19:540a (abstract 2125).
Mazzanti 2001 {published data only}
  • Mazzanti P, Massacesi C, Mattioli R, Trivisonne R, Buzzi F, De Signoribus G, et al. Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial. European Journal of Cancer. Lisbon: European Journal of Cancer, 2001; Vol. 37 Suppl 6:S50.
Novakova 2002 {published data only}
  • Novakova L, Petruzelka L, Zemanova M, Kolek V, Grygarkova I, Sixtova D, et al. Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small lung cancer (NSCLC): final results of Czech Lung Cancer Co-operative Group phase III randomized trial. Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21 Part 1:abstract 1225.
Ramlau 2007 {published data only}
  • Ramlau R, Pluzanska A, Szczesna A, Karnicka-Mlodkowska H, Wojtukiewicz M, Oklek K, et al. Results of Polish medical centres within an international randomized phase III study of docetaxel plus cisplatin and docetaxel plus carboplatin versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer. Journal of Oncology 2007;57(2):146-52.
Rodriguez 2001 {published data only}
  • Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, Fossella F, Kaukel E, et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology. 2001; Vol. 20:314a.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
American Cancer Society 2010
  • American Cancer Society. Cancer facts & figures 2010. www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-and-figures-2010 (accessed 26 June 2013).
Ardizzoni 2007
  • Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute 2007;99(11):847-57.
Azzoli 2009
  • Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology clinical practice guideline: update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology 2009;27(36):6251-66.
Baggstrom 2007
  • Baggstrom M, Stinchcombe T, Fried D, Poole C, Hensing T, Socinski M. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. Journal of Thoracic Oncology 2007;2(9):845-53.
Cochrane 2007
Eisenhauer 2009
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45(2):228-47.
Govindan 2006
  • Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006;24(28):4539-44.
Green 2003
  • Green S, Benedetti J, Crowley J. Clinical Trials in Oncology. 2nd Edition. Boca Raton, FL: Chapman & Hall/CRC, 2003.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated  September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hotta 2004
  • Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2004;22(19):3852-9.
Jiang 2007
  • Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57(3):348-58.
NCI Common Toxicity Criteria
  • National Cancer Institute. Common toxicity criteria. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf (accessed 26 June 2013).
NSCLC Collaborative Group 1995
  • NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311(7010):899-909.
Paccagnella 2004
  • Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004;43(1):83-91.
Parmar 1998
Pocock 1975
Reck 2010
  • Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology 2010;21(9):1804-9.
Reed 2005
  • Reed E. Pharmacology of cancer chemotherapy. In: DeVita VT, Lawrence TS, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. 7th Edition. Philadelphia: Lippincott Williams & Wilkins, 2005:419-26.
RevMan 2011 [Computer program]
  • The  Nordic  Cochrane  Centre, The Cochrane Collaboration. Review Manager. Version 5.1. Copenhagen: The  Nordic  Cochrane  Centre, The Cochrane Collaboration, 2011.
Sandler 2006
  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006;355(24):2542-50.
Scagliotti 2008
  • Scagliotti V, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008;26:3543-51.
Sobin 2002
  • Sobin LH, Wittekind C. Union for International Cancer Control (UICC), TNM Classification of Malignant Tumours. 6th Edition. Vol. 1, New York: Wiley-Liss, 2002.
Wright 2001